ARCHER1050: A Study of Dacomitinib vs. Gefitinib in 1st-Line Treatment Of Advanced NSCLC.

NCT01774721 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

452

Enrollment

INDUSTRY

Sponsor class

Conditions

Non-small Cell Lung Cancer With EGFR-Activating Mutations

Interventions

DRUG: Dacomitinib (PF-00299804)
DRUG: Gefitinib

Sponsor

Pfizer